PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Net Cash Provided by Financing Activities

Last Annual Value

107.98M

3-Year CAGR

-1%

5-Year CAGR

68%

10-Year CAGR

44%

PepGen Inc.

PepGen Inc. Competitors Analysis of Net Cash Provided by Financing Activities

PEPG · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
107.98M
N/A-6.1%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
20.21M
99.4%-7.8%N/A
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
141.00K
-41.1%-34.9%N/A
113.81M
15.1%8.8%N/A
23.72M
79.0%N/AN/A
60.08M
-4.1%13.6%N/A
126.40M
40.6%-5.9%N/A
29.11M
24.5%13.8%N/A
7.29M
-3.4%-55.0%N/A
-239.00K
N/AN/AN/A
77.43M
N/A4.9%16.5%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642